AstraZeneca: Tagrisso Reduced the Risk of Disease Progression or Death by 84% in Patients With Unresectable, Stage III EGFR-Mutated Lung Cancer vs. Placebo in LAURA Phase III Trial
June 04, 2024
June 04, 2024
WILMINGTON, Delaware, June 4 (TNSres) -- AstraZeneca, a biopharmaceutical company, issued the following news release on June 2, 2024:
Positive results from the LAURA Phase III trial showed AstraZeneca's TAGRISSO(R) (osimertinib) demonstrated a statistically significant and highly clinically meaningful improvement in progression-free survival (PFS) for patients with unresectable, Stage III epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) whose . . .
Positive results from the LAURA Phase III trial showed AstraZeneca's TAGRISSO(R) (osimertinib) demonstrated a statistically significant and highly clinically meaningful improvement in progression-free survival (PFS) for patients with unresectable, Stage III epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) whose . . .